![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Induction Healthcare Group Plc | LSE:INHC | London | Ordinary Share | GB00BJ0M3545 | ORD 0.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.00 | 9.00 | 11.00 | 10.00 | 10.00 | 10.00 | 0.00 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 12.88M | -17.38M | -0.1882 | -0.53 | 9.24M |
TIDMINHC
RNS Number : 2297A
Induction Healthcare Group PLC
22 September 2022
Induction Healthcare Group PLC
("Induction", the "Company", or the "Group")
Extension to publication deadline for Audited Final Results
Induction (AIM: INHC), a leading digital health platform driving transformation of healthcare systems worldwide, announces that following the grant by AIM Regulation of an extension to its 2022 annual reporting deadline, it now expects to report its final results for the year ended 31 March 2022 during October 2022, rather than on or before 30 September 2022.
The extension is required to complete the audit work for the year ended 31 March 2022 due to COVID related challenges and the impact it has had on resource availability to complete the required work.
FY22 Financial Performance
There is no change to the financial performance and, as previously reported on 21 April , results for FY22 are expected to be in-line with guidance. A significant increase in contracted annual recurring revenues ("ARR"), a key metric for the business, is expected to be delivered, with ARR for the full year of c. GBP15m (2021: GBP1.8m). Following upgraded market expectations adjusted EBITDA was at a breakeven level (2021 EBITDA loss: GBP4.1m) and net cash at 31 March 2022 was GBP7.5m (2021: GBP2.4m).
Following strong renewals of NHS England Induction Attend Anywhere ("AA") contracts, the majority with contracts renewed for 2 or 3 year terms, the Group's cash position has also increased significantly beyond period end levels.
James Balmain, CEO of Induction Healthcare, said: "FY22 was a transformational year for Induction following the acquisition of Attend Anywhere and this has continued to deliver into H1 FY23 with the AA contract renewals. I look forward to presenting our full results in October and remain confident in the future prospects of the Company, including trading for the current financial year."
ENQUIRIES
Induction Via Walbrook PR Ltd: induction@walbrookpr.com James Balmain, Chief Executive Officer Guy Mitchell, Chief Financial Officer Singer Capital Markets (Nominated Adviser and Broker) +44 (0)20 7496 3000 Philip Davies / Kailey Aliyar Walbrook PR Ltd induction@walbrookpr.com Paul McManus / Alice Woodings Mob: +44(0)7980 541 893 / +44 (0)7407 804 654
About Induction - www.inductionhealthcare.com
Induction (AIM: INHC) Induction delivers a suite of software solutions through a single integrated platform that transforms care delivery. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face - giving the communities they serve greater flexibility, control and ease of access. Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems.
Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCSEFEEFEESESU
(END) Dow Jones Newswires
September 22, 2022 02:01 ET (06:01 GMT)
1 Year Induction Healthcare Chart |
1 Month Induction Healthcare Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions